Results 21 to 30 of about 1,210,671 (242)

Image_1_Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.tif

, 2022
The contribution of natural killer (NK) cells to tumor rejection in the context of programmed death-ligand 1/programmed death 1 (PD-L1/PD-1) blockade is a matter of intense debate.
Maria-Luisa del Rio (12894632), Rodríguez-Barbosa, José Ignacio, Jose-Antonio Perez-Simon (12894635), Pérez-Simón, José A., Jose-Ignacio Rodriguez-Barbosa (12894638), Río, María Luisa del   +5 more
core   +1 more source

Identification of a Small Molecule that Binds to the PD-L1 Dimer Interface [PDF]

, 2023
In recent years, antibody drugs targeting PD-1/PD-L1 immune checkpoints have shown immense clinical benefits in cancer treatment. However, these drugs suffer from poor patient tolerance, large and difficult-to-control adverse reactions, insufficient oral
Hengwei, Bian, John Z.H., Zhang, Yifei, Qi, Wei, Xia, Liping, He, Suzhen, Dong   +5 more
core   +1 more source

The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. [PDF]

, 2012
The balance between pro-inflammatory and regulatory immune responses in determining optimal T cell activation is vital for the successful resolution of microbial infections.
Couper, Kevin N, Claser, C, Riley, Eleanor M, Julius Clemence R Hafalla, Eleanor M Riley, Kevin N Couper, de Souza, J Brian, de Souza, J. Brian, Claser Carla, Renia L., Kevin N. Couper (25399), Grau, GE, Hafalla Julius Clemence R., Laurent Renia (63769), Couper, KN, Hafalla, Julius Clemence R, Grau G.E., Couper Kevin N., Grau, Georges Emile, de Souza, JB, Riley Eleanor M., J. Brian de Souza (25406), Claser C., Renia Laurent, Riley E.M., Hafalla J.C.R., Julius Clemence R. Hafalla (185909), de Souza J.B., de Souza J. Brian, Hafalla, JC, Riley, Eleanor M., Couper K.N., Renia, Laurent, Carla Claser, Georges Emile Grau, Carla Claser (185910), Couper, Kevin N., Georges Emile Grau (185911), Renia, L, Riley, EM, J Brian de Souza, Eleanor M. Riley (25407), Grau Georges Emile, Laurent Renia, Claser, Carla   +44 more
core   +1 more source

Supporting data for "Immunophenotyping of anti-PD-L1-treated hepatocellular carcinoma"

, 2023
Hepatocellular carcinoma (HCC) is a deadly disease. The FDA recently approved the first immunotherapy, atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF-A), for advanced HCC. Nonetheless, there are still patients not responding.
Fu Wan Sit (11211570)
core   +1 more source

PD-L1 expression on platelets.

, 2021
Whole Blood, a pure platelet pellet, and platelet poor plasma from two patients, one with positive platelet PD-L1 (A) and one with negative platelet PD-L1 (D), was processed through CellSearch® in parallel with PD-L1 staining in the 4th channel.
James M. Rae (7876037), Fang Fang (38179), Erin F. Cobain (11707746), Michael Holinstat (599203), Elizabeth P. Darga (10691311), Daniel F. Hayes (2436220), Steven Kregel (289217), Kelley M. Kidwell (8929835), Christina L. Gersch (11707740), Mark Connelly (9202863), Anoop Gill (11707743), Emily M. Dolce (10691310), Costanza Paoletti (10691308), Dafydd G. Thomas (2388385), Martha E. Brown (10691325), Steven Gross (4533598)   +15 more
core   +1 more source

Vurdering av tester for PD-L1 ved urotelialt karsinom: en forenklet metodevurdering [PDF]

, 2021
Hovedbudskap: Programmed cell death ligand 1 (PD-L1) på tumorceller kan binde til Programmed cell death protein 1 på immunceller og hindre disse i å bekjempe og nøytralisere kreftsvulster.
Brurberg, Kjetil Gundro, Zinöcker, Severin, Rosness, Tor Atle   +2 more
core   +1 more source

Inhibition of tumor immune escape by blocking PD-1/PD-L1 engagement with dual-targeting molecularly imprinted polymer layer

Cancer Nanotechnology, 2023
Blocking the binding of PD-1/PD-L1 has become an effective strategy in inhibition of tumor immune escape. At present, it mainly depends on the employment of macromolecular antibodies, which target PD-1/PD-L1 protein through binding one of PD-1 or PD-L1 ...
Wenwen Ji, Bei Zhang, Xuetong Sun, Lijuan Ma, Xiangying Zhang, Wenhui Qian, Wenjuan Fu, Jianting Li, Dong Zhu   +8 more
doaj   +1 more source

PD-L1 sensitivity and specificity of antibody clone 29E.2A3 for PD-L1.

, 2021
A.Western blot of cell lysates from cultured human breast cancer cell lines known to express (MDA-MB-231) or not to express PD-L1 (MCF-7) using E1L3N Rabbit mAb, confirming the PD-L1 status of these two cell lines. B.
James M. Rae (7876037), Fang Fang (38179), Erin F. Cobain (11707746), Michael Holinstat (599203), Elizabeth P. Darga (10691311), Daniel F. Hayes (2436220), Steven Kregel (289217), Kelley M. Kidwell (8929835), Christina L. Gersch (11707740), Mark Connelly (9202863), Anoop Gill (11707743), Emily M. Dolce (10691310), Costanza Paoletti (10691308), Dafydd G. Thomas (2388385), Martha E. Brown (10691325), Steven Gross (4533598)   +15 more
core   +1 more source

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1

Journal of Translational Medicine, 2020
Background Previous studies have shown clinical relevance of programmed death-ligand 1 (PD-L1) and soluble PD-L1 (sPD-L1) in human cancers. However, still contradictory results exist.
Karolina Okła, Alicja Rajtak, Arkadiusz Czerwonka, Marcin Bobiński, Anna Wawruszak, Rafał Tarkowski, Wiesława Bednarek, Justyna Szumiło, Jan Kotarski   +8 more
doaj   +1 more source

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Biomedicines, 2021
Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu, Wei Li, Ken H. Young, Yong Li   +3 more
doaj   +1 more source